Healthcare provider profile · identity verified

Ruma Dahal, MD

Family Practice · WINCHESTER, VA · NPI 1376858498

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	610	183
Amlodipine Besylate	Amlodipine Besylate	430	123
Levothyroxine Sodium	Levothyroxine Sodium	347	86
Lisinopril	Lisinopril	284	77
Losartan Potassium	Losartan Potassium	247	67
Rosuvastatin Calcium	Rosuvastatin Calcium	240	76
Omeprazole	Omeprazole	187	60
Metformin Hcl	Metformin Hcl	154	46
Cephalexin	Cephalexin	153	102
Simvastatin	Simvastatin	149	40
Pantoprazole Sodium	Pantoprazole Sodium	124	38
Gabapentin	Gabapentin	119	36
Eliquis	Apixaban	118	30
Metoprolol Succinate	Metoprolol Succinate	115	36
Tamsulosin Hcl	Tamsulosin Hcl	114	29
Pravastatin Sodium	Pravastatin Sodium	105	29
Furosemide	Furosemide	103	36
Montelukast Sodium	Montelukast Sodium	101	26
Metoprolol Tartrate	Metoprolol Tartrate	98	29
Sertraline Hcl	Sertraline Hcl	97	26
Trazodone Hcl	Trazodone Hcl	95	24
Ozempic	Semaglutide	91	17
Ezetimibe	Ezetimibe	88	28
Hydrochlorothiazide	Hydrochlorothiazide	86	23
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	83	21
Escitalopram Oxalate	Escitalopram Oxalate	82	23
Albuterol Sulfate Hfa	Albuterol Sulfate	73	34
Atenolol	Atenolol	72	19
Trulicity	Dulaglutide	70	16
Alprazolam	Alprazolam	69	16
Allopurinol	Allopurinol	67	20
Fluoxetine Hcl	Fluoxetine Hcl	65	18
Potassium Chloride	Potassium Chloride	61	25
Shingrix	Varicella-Zoster Ge/As01b/Pf	59	45
Citalopram Hbr	Citalopram Hydrobromide	57	16
Synthroid	Levothyroxine Sodium	54	14
Duloxetine Hcl	Duloxetine Hcl	50	16
Clopidogrel	Clopidogrel Bisulfate	47	15
Tramadol Hcl	Tramadol Hcl	45	23
Prednisone	Prednisone	44	30
Zolpidem Tartrate	Zolpidem Tartrate	42	13
Januvia	Sitagliptin Phosphate	39	suppressed
Mounjaro	Tirzepatide	37	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	36	15
Hydroxyzine Hcl	Hydroxyzine Hcl	35	12
Jardiance	Empagliflozin	34	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	34	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	33	30
Cefdinir	Cefdinir	33	29
Lorazepam	Lorazepam	33	suppressed
Meloxicam	Meloxicam	32	14
Buspirone Hcl	Buspirone Hcl	31	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	31	suppressed
Bupropion Xl	Bupropion Hcl	30	suppressed
Breo Ellipta	Fluticasone/Vilanterol	29	suppressed
Carvedilol	Carvedilol	29	suppressed
Xarelto	Rivaroxaban	29	suppressed
Fluconazole	Fluconazole	28	16
Clonazepam	Clonazepam	27	suppressed
Famotidine	Famotidine	27	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	27	suppressed
Myrbetriq	Mirabegron	26	suppressed
Bupropion Hcl Sr	Bupropion Hcl	24	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	24	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	22	22
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	22	suppressed
Valsartan	Valsartan	22	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Estradiol	Estradiol	21	suppressed
Glimepiride	Glimepiride	21	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	21	21
Spironolactone	Spironolactone	21	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	20	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Azithromycin	Azithromycin	19	18
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	19	suppressed
Clobetasol Propionate	Clobetasol Propionate	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Alendronate Sodium	Alendronate Sodium	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Irbesartan	Irbesartan	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Metformin Hcl Er	Metformin Hcl	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	16	suppressed
Levemir Flexpen	Insulin Detemir	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Topiramate	Topiramate	15	suppressed
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	14	14
Gemfibrozil	Gemfibrozil	14	suppressed
Novolog Flexpen	Insulin Aspart	14	suppressed
Nystatin	Nystatin	14	11
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Veo Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	14	suppressed
Verapamil Er	Verapamil Hcl	14	suppressed
Bumetanide	Bumetanide	13	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	13	suppressed
Finasteride	Finasteride	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Rybelsus	Semaglutide	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Celecoxib	Celecoxib	12	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	12	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	12	suppressed
Klayesta	Nystatin	12	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	12	suppressed
Bupropion Hcl	Bupropion Hcl	11	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Lovastatin	Lovastatin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error